PeptiDream
4587.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥18.5bn | ¥46.7bn | ¥28.7bn | ¥26.9bn | ¥9.4bn | — |
| Operating income | −¥5.0bn | ¥21.1bn | ¥6.8bn | ¥9.0bn | ¥4.1bn | — |
| Ordinary income | — | — | — | ¥8.1bn | — | — |
| Net income (owners) | −¥3.7bn | ¥15.0bn | ¥3.0bn | ¥7.6bn | ¥2.6bn | — |
| Total assets | ¥77.0bn | ¥92.8bn | ¥69.5bn | ¥63.9bn | ¥27.0bn | ¥26.1bn |
| Net assets / equity | ¥51.5bn | ¥56.8bn | ¥40.3bn | ¥32.0bn | ¥25.4bn | ¥21.3bn |
| Operating cash flow | −¥13.3bn | ¥23.8bn | ¥12.4bn | −¥83m | ¥6.7bn | — |
| EPS (basic) | ¥-28.99 | ¥115.85 | ¥23.41 | ¥58.19 | ¥19.96 | — |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 17
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 89 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 213 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 91 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 223 figures · EDINET |
| 2023-01-01 → 2023-12-31 | AnnualAmended | 226 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 91 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 91 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 226 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 115 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2Amended | 115 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1Amended | 88 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 115 figures · EDINET |
| 2022-01-01 → 2022-12-31 | AnnualAmended | 218 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 88 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 218 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 117 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 117 figures · EDINET |
23 more reports are still being processed.
Segments · FY ended 2025-12
| Segment | External sales | Profit |
|---|---|---|
| Drug Discovery And Development Business | ¥2.8bn | −¥5.4bn |
| Radiopharmaceuticals Business | ¥15.7bn | ¥435m |
| Adjustments & eliminations | — | — |
| Total | ¥18.5bn | −¥4.9bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.